Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

API-CAT establishes reduced-dose apixaban "as an appropriate regimen" for anticoagulation ... trial demonstrate lower rates ...

A study shows reduced-dose apixaban effectively prevents recurrent blood clots in cancer patients, lowering bleeding risks ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning ...

On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant ... a 1:1 ratio to receive oral apixaban at a reduced (2.5 ...

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to ...

It has a plasma elimination half-life of 12 hours and has been ... without the need for anticoagulation monitoring or dosage adjustment. Apixaban has multiple elimination pathways, and its ...

A recent study from National Taiwan University Hospital shows that apixaban, a blood-thinning medication, can help prevent ...

CHICAGO — For patients with cancer requiring extended anticoagulant therapy, a strategy of reduced-dose apixaban was noninferior to full-dose apixaban for prevention of cancer-associated ...

API-CAT establishes reduced-dose apixaban "as an appropriate regimen ... lower rates of clinically relevant bleeding in the half-dose DOAC arm than the full-dose DOAC arm." He predicted an ...